To compare the efficacy and safety of ranibizumab 0.5 mg , guided by visual acuity ( VA ) stabilization or disease activity criteria , versus verteporfin photodynamic therapy ( vPDT ) in patients with visual impairment due to myopic choroidal neovascularization ( CNV ) .